5/15/2025
Last update
5/15/2025
Reviewed By
Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 3 Researches
8.7
USERS' SCORE
Good
Based on 1 Review
8.4
Supplement Facts
Serving Size: 1 Vegetable Capsule
Amount Per Serving
%DV
L-Lysine (as L-lysine HCl) (Free Form)
500 mg
**
Top Medical Research Studies
9
We investigated the impact of carbocysteine-lysine on bronchial mucus in patients suffering from chronic bronchitis. Over a short treatment span of just four days, participants received a daily dose of 2.7 grams of carbocysteine-lysine.
Before treatment, we evaluated the viscosity (thickness) of their mucus and how effectively it could be cleared from the airways. After treatment, we noted a substantial decrease in mucus viscosity, with reductions of up to 67%, alongside improvements in mucociliary transport of up to 41%.
What’s particularly noteworthy is that these positive changes persisted even eight days after the treatment ended, suggesting a lasting benefit of the medication. However, we observed no significant impact on mucus elasticity, indicating that while carbocysteine-lysine improves mucus clearance, it may not affect the elasticity aspect as significantly. Overall, these results hint at a 'post-mucoactive' effect of carbocysteine-lysine in managing chronic bronchitis symptoms.
Before treatment, we evaluated the viscosity (thickness) of their mucus and how effectively it could be cleared from the airways. After treatment, we noted a substantial decrease in mucus viscosity, with reductions of up to 67%, alongside improvements in mucociliary transport of up to 41%.
What’s particularly noteworthy is that these positive changes persisted even eight days after the treatment ended, suggesting a lasting benefit of the medication. However, we observed no significant impact on mucus elasticity, indicating that while carbocysteine-lysine improves mucus clearance, it may not affect the elasticity aspect as significantly. Overall, these results hint at a 'post-mucoactive' effect of carbocysteine-lysine in managing chronic bronchitis symptoms.
Read More
9
We conducted a thorough evaluation of how carbocysteine lysine salt monohydrate, which includes l-lysine, affects patients with chronic obstructive bronchitis. In a well-structured multicenter trial, we involved 662 outpatients who were split into three groups. These groups received either a daily dose of SCMC-Lys, intermittent treatment, or a placebo for six months during the colder months of the year.
Our findings showed that those on continuous treatment with SCMC-Lys had fewer exacerbations compared to the placebo group. Specifically, 29.6% of patients on SCMC-Lys experienced at least one exacerbation, compared to 45.9% in the placebo group. Furthermore, we observed that patients on continuous SCMC-Lys had an extended time before experiencing their first exacerbation and a noticeable reduction in acute respiratory illness days. This was also linked to a decreased need for antibiotics during the treatment period.
However, it’s important to note that the intermittent treatment did not show significant benefits over the placebo. Overall, we concluded that continuous administration of the SCMC-Lys formulation is effective in reducing exacerbations in chronic obstructive bronchitis and is well tolerated by patients. Still, we cannot confidently attribute these positive results solely to l-lysine without additional studies focusing specifically on that component.
Our findings showed that those on continuous treatment with SCMC-Lys had fewer exacerbations compared to the placebo group. Specifically, 29.6% of patients on SCMC-Lys experienced at least one exacerbation, compared to 45.9% in the placebo group. Furthermore, we observed that patients on continuous SCMC-Lys had an extended time before experiencing their first exacerbation and a noticeable reduction in acute respiratory illness days. This was also linked to a decreased need for antibiotics during the treatment period.
However, it’s important to note that the intermittent treatment did not show significant benefits over the placebo. Overall, we concluded that continuous administration of the SCMC-Lys formulation is effective in reducing exacerbations in chronic obstructive bronchitis and is well tolerated by patients. Still, we cannot confidently attribute these positive results solely to l-lysine without additional studies focusing specifically on that component.
Read More
8
We investigated how a treatment involving stepronine-lysine salt affects bronchial mucus in patients with bronchitis. Our study was well-structured, featuring a double-blind, randomized design to ensure reliable results. We measured the rheological properties, or flow characteristics, of bronchial secretions from participants before and after treatment.
In our findings, we noted that participants receiving stepronine-lysine showed a significant reduction in the viscosity of their mucus, meaning their secretions became thinner and easier to expel. This is promising as thicker mucus can contribute to breathing difficulties in bronchitis patients.
Conversely, the placebo group saw no change in mucus viscosity or elasticity, indicating that the observed benefits were likely due to the treatment rather than other factors. However, while this study highlights some positive effects of stepronine-lysine, it also suggests that the specific role of l-lysine alone remains unclear since it was tested in conjunction with stepronine. Thus, the isolated effects of l-lysine on bronchitis need further investigation.
In our findings, we noted that participants receiving stepronine-lysine showed a significant reduction in the viscosity of their mucus, meaning their secretions became thinner and easier to expel. This is promising as thicker mucus can contribute to breathing difficulties in bronchitis patients.
Conversely, the placebo group saw no change in mucus viscosity or elasticity, indicating that the observed benefits were likely due to the treatment rather than other factors. However, while this study highlights some positive effects of stepronine-lysine, it also suggests that the specific role of l-lysine alone remains unclear since it was tested in conjunction with stepronine. Thus, the isolated effects of l-lysine on bronchitis need further investigation.
Read More
Most Useful Reviews
7
Doctor's recommendation
7 people found this helpful
Physician Recommended! My 90-year-old mother-in-law became ill with bronchitis. After recovery, her doctor recommended this supplement to strengthen her lungs. She has since taken it without any discomfort. Although I can't speak for the doctor’s wisdom, what I see is very promising.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 3 Researches
8.7
- All Researches
9
We conducted a thorough evaluation of how carbocysteine lysine salt monohydrate, which includes l-lysine, affects patients with chronic obstructive bronchitis. In a well-structured multicenter trial, we involved 662 outpatients who were split into three groups. These groups received either a daily dose of SCMC-Lys, intermittent treatment, or a placebo for six months during the colder months of the year.
Our findings showed that those on continuous treatment with SCMC-Lys had fewer exacerbations compared to the placebo group. Specifically, 29.6% of patients on SCMC-Lys experienced at least one exacerbation, compared to 45.9% in the placebo group. Furthermore, we observed that patients on continuous SCMC-Lys had an extended time before experiencing their first exacerbation and a noticeable reduction in acute respiratory illness days. This was also linked to a decreased need for antibiotics during the treatment period.
However, it’s important to note that the intermittent treatment did not show significant benefits over the placebo. Overall, we concluded that continuous administration of the SCMC-Lys formulation is effective in reducing exacerbations in chronic obstructive bronchitis and is well tolerated by patients. Still, we cannot confidently attribute these positive results solely to l-lysine without additional studies focusing specifically on that component.
Our findings showed that those on continuous treatment with SCMC-Lys had fewer exacerbations compared to the placebo group. Specifically, 29.6% of patients on SCMC-Lys experienced at least one exacerbation, compared to 45.9% in the placebo group. Furthermore, we observed that patients on continuous SCMC-Lys had an extended time before experiencing their first exacerbation and a noticeable reduction in acute respiratory illness days. This was also linked to a decreased need for antibiotics during the treatment period.
However, it’s important to note that the intermittent treatment did not show significant benefits over the placebo. Overall, we concluded that continuous administration of the SCMC-Lys formulation is effective in reducing exacerbations in chronic obstructive bronchitis and is well tolerated by patients. Still, we cannot confidently attribute these positive results solely to l-lysine without additional studies focusing specifically on that component.
Read More
9
We investigated the impact of carbocysteine-lysine on bronchial mucus in patients suffering from chronic bronchitis. Over a short treatment span of just four days, participants received a daily dose of 2.7 grams of carbocysteine-lysine.
Before treatment, we evaluated the viscosity (thickness) of their mucus and how effectively it could be cleared from the airways. After treatment, we noted a substantial decrease in mucus viscosity, with reductions of up to 67%, alongside improvements in mucociliary transport of up to 41%.
What’s particularly noteworthy is that these positive changes persisted even eight days after the treatment ended, suggesting a lasting benefit of the medication. However, we observed no significant impact on mucus elasticity, indicating that while carbocysteine-lysine improves mucus clearance, it may not affect the elasticity aspect as significantly. Overall, these results hint at a 'post-mucoactive' effect of carbocysteine-lysine in managing chronic bronchitis symptoms.
Before treatment, we evaluated the viscosity (thickness) of their mucus and how effectively it could be cleared from the airways. After treatment, we noted a substantial decrease in mucus viscosity, with reductions of up to 67%, alongside improvements in mucociliary transport of up to 41%.
What’s particularly noteworthy is that these positive changes persisted even eight days after the treatment ended, suggesting a lasting benefit of the medication. However, we observed no significant impact on mucus elasticity, indicating that while carbocysteine-lysine improves mucus clearance, it may not affect the elasticity aspect as significantly. Overall, these results hint at a 'post-mucoactive' effect of carbocysteine-lysine in managing chronic bronchitis symptoms.
Read More
8
We investigated how a treatment involving stepronine-lysine salt affects bronchial mucus in patients with bronchitis. Our study was well-structured, featuring a double-blind, randomized design to ensure reliable results. We measured the rheological properties, or flow characteristics, of bronchial secretions from participants before and after treatment.
In our findings, we noted that participants receiving stepronine-lysine showed a significant reduction in the viscosity of their mucus, meaning their secretions became thinner and easier to expel. This is promising as thicker mucus can contribute to breathing difficulties in bronchitis patients.
Conversely, the placebo group saw no change in mucus viscosity or elasticity, indicating that the observed benefits were likely due to the treatment rather than other factors. However, while this study highlights some positive effects of stepronine-lysine, it also suggests that the specific role of l-lysine alone remains unclear since it was tested in conjunction with stepronine. Thus, the isolated effects of l-lysine on bronchitis need further investigation.
In our findings, we noted that participants receiving stepronine-lysine showed a significant reduction in the viscosity of their mucus, meaning their secretions became thinner and easier to expel. This is promising as thicker mucus can contribute to breathing difficulties in bronchitis patients.
Conversely, the placebo group saw no change in mucus viscosity or elasticity, indicating that the observed benefits were likely due to the treatment rather than other factors. However, while this study highlights some positive effects of stepronine-lysine, it also suggests that the specific role of l-lysine alone remains unclear since it was tested in conjunction with stepronine. Thus, the isolated effects of l-lysine on bronchitis need further investigation.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.4
- All Reviews
- Positive Reviews
- Negative Reviews
7
Doctor's recommendation
7 people found this helpful
Physician Recommended! My 90-year-old mother-in-law became ill with bronchitis. After recovery, her doctor recommended this supplement to strengthen her lungs. She has since taken it without any discomfort. Although I can't speak for the doctor’s wisdom, what I see is very promising.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
- Allegra L, Cordaro CI, Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. Respiration. 1996;63:174.
- Braga PC, Allegra L, Rampoldi C, Ornaghi A, Beghi G. Long-lasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteine-lysine to patients with chronic bronchitis. Respiration. 1990;57:353.
- Braga PC, Bossi R, Allegra L. Rheological modifications of mucus in chronic bronchitic patients after treatment with stepronine-lysine salt. Drugs Exp Clin Res. 1987;13:707.
